Comparison of three methods for susceptibility testing of Mycobacterium avium subsp. paratuberculosis to 11 antimicrobial drugs

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 2, 2009, Pages 310-316

  Krishnan, Manju Y ^a   Manning, Elizabeth J B ^a   Collins, Michael T ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Agar dilution; BACTEC; MGIT; MIC

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; DAPSONE; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; RIFABUTIN; RIFAMPICIN;

AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BROTH DILUTION; CONTROLLED STUDY; HUMAN; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM PARATUBERCULOSIS; NONHUMAN;

ANIMALS; ANTI-BACTERIAL AGENTS; CATTLE; CROHN DISEASE; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS; PARATUBERCULOSIS;

EID: 67650708893     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp184     Document Type: Article

References (39)

1. Abubakar I, Myhill D, Aliyu SH et al. Detection of Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic acid-based techniques: A systematic review and meta-analysis. Inflamm Bowel Dis 2008; 14: 401-10.
2. Behr MA, Kapur V. The evidence for Mycobacterium paratuberculosis in Crohn's disease. Curr Opin Gastroenterol 2008; 24: 17-21.
3. Feller M, Huwiler K, Stephan R et al. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: A systematic review and meta-analysis. Lancet Infect Dis 2007; 7: 607-13.
4. Lowe AM, Yansouni CP, Behr MA. Causality and gastrointestinal infections: Koch, Hill, and Crohn's. Lancet Infect Dis 2008; 8 720-6.
5. Scanu AM, Bull TJ, Cannas S et al. Mycobacterium avium subspecies paratuberculosis infection in cases of irritable bowel syndrome and comparison with Crohn's disease and Johne's disease: Common neural and immune pathogenicities. J Clin Microbiol 2007; 45: 3883-90.
6. Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000; 95: 725-9.
7. Williams SL, Harris NB, Barletta RG. Development of a firefly luciferase-based assay for determining antimicrobial susceptibility of Mycobacterium avium subsp. paratuberculosis. J Clin Microbiol 1999; 37: 304-9.
8. Borody TJ, Bilkey S, Wettstein AR et al. Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars. Dig Liver Dis 2007; 39: 438-44.
9. Goodgame RW, Kimball K, Akram S et al. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment Pharmacol Ther 2001; 15: 1861-6.
10. Inoue S, Nakase H, Matsuura M et al. Open label trial of clarithromycin therapy in Japanese patients with Crohn's disease. J Gastroenterol Hepatol 2007; 22: 984-8.
11. Leiper K, Martin K, Ellis A et al. Clinical trial: Randomized study of clarithromycin versus placebo in active Crohn's disease. Aliment Pharmacol Ther 2008; 27: 1233-9.
12. Leiper K, Morris AI, Rhodes JM. Open label trial of oral clarithromycin in active Crohn's disease. Aliment Pharmacol Ther 2000; 14: 801-6.
13. Selby W, Pavli P, Crotty B et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007; 132: 2313-9.
14. Shafran I, Kugler L, El-Zaatari FA et al. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig Liver Dis 2002; 34: 22-8.
15. Behr MA, Hanley J. Antimycobacterial therapy for Crohn's disease: A reanalysis. Lancet Infect Dis 2008; 8: 344.
16. Kuenstner JT. The Australian antibiotic trial in Crohn's disease: alternative conclusions from the same study. Gastroenterology 2007; 133: 1742-3; author reply 1745-6.
17. Greenstein RJ, Su L, Haroutunian V et al. On the action of methotrexate and 6-mercaptopurine on M. avium subspecies paratuberculosis. PLoS ONE 2007; 2: E161.
18. Greenstein RJ, Su L, Juste RA et al. On the action of cyclosporine A, rapamycin and tacrolimus on M. avium including subspecies paratuberculosis. PLoS ONE 2008; 3: E2496.
19. Parrish NM, Ko CG, Dick JD et al. Growth, Congo Red agar colony morphotypes and antibiotic susceptibility testing of Mycobacterium avium subspecies paratuberculosis. Clin Med Res 2004; 2: 107-14.
20. Rastogi N, Goh KS, Labrousse V. Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol. Antimicrob Agents Chemother 1992; 36: 2843-6.
21. Siddiqi SH, Heifets LB, Cynamon MH et al. Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates. J Clin Microbiol 1993; 31: 2332-8.
22. Grant IR, Kirk RB, Hitchings E et al. Comparative evaluation of the MGIT and BACTEC culture systems for the recovery of Mycobacterium avium subsp. paratuberculosis from milk. J Appl Microbiol 2003; 95: 196-201.
23. Somoskövi A, Ködmön C, Lantos A et al. Comparison of recoveries of Mycobacterium tuberculosis using the automated BACTEC MGIT 960 system, the BACTEC 460 TB system, and Löwenstein-Jensen medium. J Clin Microbiol 2000; 38: 2395-7.
24. Garrigó M, Aragón LM, Alcaide F et al. Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2007; 45: 1766-70.
25. Rüsch-Gerdes S, Pfyffer GE, Casal M et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-92.
26. Shin SJ, Han JH, Manning EJ et al. Rapid and reliable method for quantification of Mycobacterium paratuberculosis by use of the BACTEC MGIT 960 system. J Clin Microbiol 2007; 45: 1941-8.
27. Krishnan MY, Manning EJ, Collins MT. Stability of antibacterial agents in MGIT™ ParaTB medium. Int J Antimicrob Agents 2009; 33: 186-7.
28. Shin SJ, Collins MT. Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. Antimicrob Agents Chemother 2008; 52: 418-26.
29. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes: Approved Standard M24-A. NCCLS,Wayne, PA, USA, 2003.
30. Lambrecht RS, Carriere JF, Collins MT. A model for analyzing growth kinetics of a slowly growing Mycobacterium sp. Appl Environ Microbiol 1988; 54: 910-6.
31. Inderleid CB, Salfinger M. Antimicrobial agents and susceptibility tests: Mycobacteria. In: Murray PR, Baron EJ, Pfaller MAeds. Manual of Clinical Microbiology. Washington, DC: ASM Press, 1995; 1385-404.
32. Heifets L. Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob Agents Chemother 1996; 40: 1759-67.
33. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001; 119: 1114-22.
34. Peloquin CA, Jaresko GS, Yong CL et al. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 1997; 41: 2670-9.
35. Pieters FA, Zuidema J. The pharmacokinetics of dapsone after oral administration to healthy volunteers. Br J Clin Pharmacol 1986; 22: 491-4.
36. Bemer-Melchior P, Bryskier A, Drugeon HB. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. J Antimicrob Chemother 2000; 46: 571-6.
37. Heifets LB, Iseman MD, Lindholm-Levy PJ. Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuberculosis. Antimicrob Agents Chemother 1986; 30: 927-32.
38. Piersimoni C, Nista D, Bornigia S et al. Evaluation of a new method for rapid drug susceptibility testing of Mycobacterium avium complex isolates by using the mycobacteria growth indicator tube. J Clin Microbiol 1998; 36: 64-7.
39. Zanetti S, Molicotti P, Cannas S et al. 'In vitro' activities of antimycobacterial agents against Mycobacterium avium subsp. paratuberculosis linked to Crohn's disease and paratuberculosis. Ann Clin Microbiol Antimicrob 2006; 5: 27.